A Randomized, Double-Blind, Vehicle Controlled Study To Evaluate The Safety, Tolerability, And Efficacy Of DMT210 Gel In Adult Patients With Moderate To Severe Acne Rosacea

Trial Profile

A Randomized, Double-Blind, Vehicle Controlled Study To Evaluate The Safety, Tolerability, And Efficacy Of DMT210 Gel In Adult Patients With Moderate To Severe Acne Rosacea

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs DMT 200 (Primary)
  • Indications Rosacea
  • Focus Therapeutic Use
  • Sponsors Dermata Therapeutics
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 07 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 18 Jan 2017 According to Dermata Therapeutics media release, first patient has been dosed in the study and top line results are expected in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top